SAB Biotherapeutics
SABS
28 hedge funds and large institutions have $6.78M invested in SAB Biotherapeutics in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 14 increasing their positions, 6 reducing their positions, and 9 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 6
0.29% less ownership
Funds ownership: 0.71% → 0.42% (-0.29%)
18% less funds holding
Funds holding: 34 → 28 (-6)
67% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 9
73% less capital invested
Capital invested by funds: $25.4M → $6.78M (-$18.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Creative Planning
Overland Park,
Kansas
|
+$215K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$176K |
| 3 |
SCM
Shaolin Capital Management
Miami,
Florida
|
+$163K |
| 4 |
State Street
Boston,
Massachusetts
|
+$139K |
| 5 |
AWM
AE Wealth Management
Topeka,
Kansas
|
+$86.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FPB
First PREMIER Bank
Sioux Falls,
South Dakota
|
-$6.5M |
| 2 |
RCM
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
|
-$5.52M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$189K |
| 4 |
VF
Virtu Financial
New York
|
-$120K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$118K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Rockefeller Capital Management
New York
| $4K | +$1.85K | +40 | +57% |
|
|
MCC
27
Money Concepts Capital
Palm Beach Gardens,
Florida
| $1K | +$1.15K | +25 | New |
|
|
FPB
28
First PREMIER Bank
Sioux Falls,
South Dakota
| – | -$6.5M | -83,256 | Closed |
|
|
RCM
29
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
| – | -$5.52M | -54,666 | Closed |
|
|
30
Citadel Advisors
Miami,
Florida
| – | -$189K | -2,423 | Closed |
|
|
VF
31
Virtu Financial
New York
| – | -$120K | -1,538 | Closed |
|
|
32
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$118K | -1,512 | Closed |
|
|
CSS
33
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$101K | -1,290 | Closed |
|
|
NFG
34
Nadler Financial Group
Deerfield,
Illinois
| – | -$86K | -1,100 | Closed |
|
35
Charles Schwab
San Francisco,
California
| – | -$79K | -1,000 | Closed |
|
36
Marshall Wace
London,
United Kingdom
| – | -$3K | -50 | Closed |
|
SABS Hedge Fund Activity: Q1 2022 in Review
28 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics (SABS) for Q1 2022, worth a combined $6.78M — down 73% from $25.4M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of SABS and 3 opened new positions — a net loss of 6 holders — while 6 trimmed existing stakes and 14 added.
The largest buyer was Creative Planning, opening a new position worth an estimated $215K. The largest seller was First PREMIER Bank, exiting entirely with an estimated $6.5M sold.
- 28 institutional investors held SAB Biotherapeutics (SABS) as of Q1 2022, down from 34 in Q4 2021.
- Funds reported $6.78M of SAB Biotherapeutics stock for Q1 2022, down 73% quarter-over-quarter.
- 3 funds opened new SAB Biotherapeutics positions in Q1 2022 and 9 closed out, a net change of -6 holders.
- The largest SAB Biotherapeutics buyer in Q1 2022 was Creative Planning, an estimated $215K added.
- The largest SAB Biotherapeutics seller in Q1 2022 was First PREMIER Bank, an estimated $6.5M sold.
Based on aggregated 13F filings for Q1 2022.